S&P 500   3,001.57 (-0.17%)
DOW   26,840.61 (+0.05%)
QQQ   192.31 (-0.56%)
AAPL   240.48 (-0.01%)
FB   183.20 (-3.46%)
MSFT   136.89 (-1.12%)
GOOGL   1,240.89 (-0.27%)
CGC   20.96 (+3.00%)
NVDA   196.44 (+0.22%)
MU   44.80 (-0.93%)
BABA   169.53 (-2.30%)
GE   8.96 (+1.94%)
AMD   31.61 (-1.34%)
T   38.22 (-0.03%)
F   9.04 (+0.11%)
NFLX   266.85 (-4.03%)
BAC   31.15 (+0.42%)
GILD   66.06 (+1.30%)
DIS   132.75 (+1.91%)
S&P 500   3,001.57 (-0.17%)
DOW   26,840.61 (+0.05%)
QQQ   192.31 (-0.56%)
AAPL   240.48 (-0.01%)
FB   183.20 (-3.46%)
MSFT   136.89 (-1.12%)
GOOGL   1,240.89 (-0.27%)
CGC   20.96 (+3.00%)
NVDA   196.44 (+0.22%)
MU   44.80 (-0.93%)
BABA   169.53 (-2.30%)
GE   8.96 (+1.94%)
AMD   31.61 (-1.34%)
T   38.22 (-0.03%)
F   9.04 (+0.11%)
NFLX   266.85 (-4.03%)
BAC   31.15 (+0.42%)
GILD   66.06 (+1.30%)
DIS   132.75 (+1.91%)
Log in

Collegium Pharmaceutical Stock Price, News & Analysis (NASDAQ:COLL)

$11.55
-0.32 (-2.70 %)
(As of 10/22/2019 03:11 PM ET)
Today's Range
$11.47
Now: $11.55
$11.97
50-Day Range
$10.52
MA: $11.54
$12.81
52-Week Range
$10.01
Now: $11.55
$19.83
Volume209,832 shs
Average Volume309,897 shs
Market Capitalization$386.58 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$280.41 million
Cash Flow$2.16 per share
Book Value$2.75 per share

Profitability

Net Income$-39,130,000.00

Miscellaneous

Employees266
Market Cap$386.58 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.


Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) released its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.05. The specialty pharmaceutical company had revenue of $75.04 million for the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. Collegium Pharmaceutical's quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.40) EPS. View Collegium Pharmaceutical's Earnings History.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Collegium Pharmaceutical.

What price target have analysts set for COLL?

6 analysts have issued 1-year price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $33.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $26.20 in the next year. This suggests a possible upside of 127.4% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

What is the consensus analysts' recommendation for Collegium Pharmaceutical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Has Collegium Pharmaceutical been receiving favorable news coverage?

Media coverage about COLL stock has trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Collegium Pharmaceutical.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 2,810,000 shares, a decline of 7.0% from the August 15th total of 3,020,000 shares. Based on an average daily trading volume, of 275,600 shares, the short-interest ratio is presently 10.2 days. Approximately 10.1% of the company's stock are sold short. View Collegium Pharmaceutical's Current Options Chain.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), Celgene (CELG), NVIDIA (NVDA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:
  • Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35)

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who are Collegium Pharmaceutical's major shareholders?

Collegium Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Strs Ohio (0.16%), Virginia Retirement Systems ET AL (0.13%), Campbell & CO Investment Adviser LLC (0.03%), Nisa Investment Advisors LLC (0.03%) and Meeder Asset Management Inc. (0.03%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

Which major investors are buying Collegium Pharmaceutical stock?

COLL stock was purchased by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, Meeder Asset Management Inc. and Strs Ohio. View Insider Buying and Selling for Collegium Pharmaceutical.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $11.52.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $385.57 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.


MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  287 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel